摘要
目的 我国在抗肿瘤药物价值评估方面尚处于初级阶段,缺乏成熟的药物价值评估体系,通过对DrugAbacus交互式计算器的分析和探讨,为我国建立基于价值评估的药物经济学模型提供参考,为临床医生和患者选择治疗方案提供有价值的参考意见。方法 通过文献检索、数据查询等对DrugAbacus交互式计算器的价值构成因素和数据来源进行分析,并根据基线数值对抗肿瘤药物进行价格评估。结果 抗肿瘤药物Afinitor,用于治疗肾癌、胰腺癌以及乳腺癌时,实际价格均高于建议价格;抗肿瘤药物Avastin用于结肠癌的治疗时,实际价格与建议价格相差不大;Halaven的建议价格始终是高于实际价格的,即该药物的价格至少是合理的甚至价格偏低,Ixempra的价格偏高,所以认为使用药物Halaven比使用药物Ixempra能节省更多的费用。结论 DrugAbacus方法对药品定价所应该考虑的因素进行了复杂的分析,虽然存在局限性,但是该方法在很大程度上反映了社会对创新型药物价值的评估,可以为我国药品定价提供参考。
Abstract
OBJECTIVE China is still in its infancy in assessing the value of anti-tumor drugs, lacking a mature drug value assessment system. To provide reference for the establishment of a pharmacoeconomic model based on value assessment in China, and provide valuable reference for clinicians and patients to choose treatment options, Through the analysis and discussion of the DrugAbacus interactive calculator. METHODS The value components and data sources of the DrugAbacus interactive calculator were analyzed by literature search, data query, etc., and the price of the anti-tumor drugs was evaluated according to the baseline values. RESULTS The actual price of anti-cancer drug afinitor is higher than the recommended price when used to treat kidney cancer, pancreatic cancer and breast cancer. When the anti-tumor drug avastin is used in the treatment of colon cancer, the actual price is not much different from the recommended price. Halaven′s suggested price is always higher than the actual price, that is, the price of the drug is at least reasonable or even low, and Ixempra′s price is high, so using the drug Halaven can save more money than using the drug Ixempra. CONCLUSION The DrugAbacus method provides a complex analysis of the factors that should be considered in drug pricing. Although there are limitations, this method reflects to a large extent the evaluation of the value of innovative drugs in society, which can provide reference for drug pricing in China.
关键词
DrugAbacus /
抗肿瘤药物 /
药品价格
{{custom_keyword}} /
Key words
DrugAbacus /
anti-tumor drug /
drug price
{{custom_keyword}} /
王素素, 张方.
DrugAbacus方法在抗肿瘤药物定价方面的应用[J]. 中国药学杂志, 2019, 54(20): 1715-1719 https://doi.org/10.11669/cpj.2019.20.015
WANG Su-su, ZHANG Fang.
Application of DrugAbacus Method in Pricing Antitumor Drugs[J]. Chinese Pharmaceutical Journal, 2019, 54(20): 1715-1719 https://doi.org/10.11669/cpj.2019.20.015
中图分类号：
R95
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SCHNIPPER L E. American society of clinical oncology statement:a conceptual framework to assess the value of cancer treatment options[J]. J Clin Oncol, 2015, 33(23):2563-2577.
[2] KIM C, PRASAD V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival:an analysis of 5 years of US Food and Drug Administration approvals[J]. JAMA Intern Med, 2015,175(12):1992-1994.
[3] Meizhongyaoyuan.Life is no longer priceless: The American Society of Clinical Oncology (ASCO) has released the "Value Framework" of anticancer drugs "(value framework)[EB/OL].[2018-01-08]. http://www.biodiscover.com/news/politics/120048.html.
[4] WESTRICH K, BUELT L, DUBOIS R W. Why value framework assessments arrive at different conclusions: a multiple myeloma case study[J]. J Manag Care Spec Pharm,2017,23(6-a Suppl):28-33.
[5] Memorial Sloan Kettering Cancer Center Drug Pricing Lab. Methods. http:// drugpricinglab.org/tools/drug-abacus/methods/#faqs. 2017-06-08.
[6] COOPER K, SMITH H J, LEATH C A, et al. Using DrugAbacus to determine the value of PD-1 inhibitors in ovarian cancer:how much should they cost?[J]. Gynecol Oncol, 2017,145:165.
[7] SMITH H J, COOPER K, LEATH C A, et al. Using value-based tools to determine the value of bevacizumab in cer-vicaland ovarian cancer[J]. Gynecol Oncol, 2017,145:62-63.
[8] XIA X M, FDA approved Halaven (eribulin mesylate) for the treatment of liposarcoma [J]. J Guangdong Univ Pharmacy (广东药学院学报),,2016,32(01):110.
[9] HOU Y W. Drug Abacus——New Pricing Scheme for Anticancer Drugs EB/OL]. (2018-10-29)[2015-06-25].https://news.yaozh.com/archive/8236.html.
[10] PETER B. Bach. A New Way to Define Value in Drug Pricing[EB/OL].[2018-01-08].https://catalyst.nejm.org/a-new-way-to-define-value-in-drug-pricing/.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
辽宁省教育厅服务地方项目资助(2017WFW05)
{{custom_fund}}
PDF(1275 KB)
